Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8597684	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (2 years from now)
US10086087	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (2 years from now)
US8747902	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (2 years from now)
US9675703	TRIS PHARMA INC	Modified release formulations containing drug - ion exchange resin complexes	Mar, 2027 (2 years from now)
US8883217	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (2 years from now)
US8062667	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)
US11590228	TRIS PHARMA INC	Extended release amphetamine compositions	Sep, 2036 (12 years from now)

Dyanavel Xr is owned by Tris Pharma Inc.

Dyanavel Xr contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.

Dyanavel Xr has a total of 7 drug patents out of which 0 drug patents have expired.

Dyanavel Xr was authorised for market use on 19 October, 2015.

Dyanavel Xr is available in suspension, extended release;oral dosage forms.

Dyanavel Xr can be used as method of treating attention deficit hyperactivity disorder.

The generics of Dyanavel Xr are possible to be released after 07 September, 2036.

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 19, 2018

Market Authorisation Date: 19 October, 2015

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Dyanavel Xr patents expiration